{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T20:12:59Z","timestamp":1795119179318,"version":"4.10.3"},"reference-count":45,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,10,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Malignant cells have a higher nicotinamide adenine dinucleotide (NAD+) turnover rate than normal cells, making this biosynthetic pathway an attractive target for cancer treatment. Here we investigated the biologic role of a rate-limiting enzyme involved in NAD+ synthesis, Nampt, in multiple myeloma (MM). Nampt-specific chemical inhibitor FK866 triggered cytotoxicity in MM cell lines and patient MM cells, but not normal donor as well as MM patients PBMCs. Importantly, FK866 in a dose-dependent fashion triggered cytotoxicity in MM cells resistant to conventional and novel anti-MM therapies and overcomes the protective effects of cytokines (IL-6, IGF-1) and bone marrow stromal cells. Nampt knockdown by RNAi confirmed its pivotal role in maintenance of both MM cell viability and intracellular NAD+ stores. Interestingly, cytotoxicity of FK866 triggered autophagy, but not apoptosis. A transcriptional-dependent (TFEB) and independent (PI3K\/mTORC1) activation of autophagy mediated FK866 MM cytotoxicity. Finally, FK866 demonstrated significant anti-MM activity in a xenograft-murine MM model, associated with down-regulation of ERK1\/2 phosphorylation and proteolytic cleavage of LC3 in tumor cells. Our data therefore define a key role of Nampt in MM biology, providing the basis for a novel targeted therapeutic approach.<\/jats:p>","DOI":"10.1182\/blood-2012-03-416776","type":"journal-article","created":{"date-parts":[[2012,9,7]],"date-time":"2012-09-07T00:47:37Z","timestamp":1346978857000},"page":"3519-3529","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":136,"title":["Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1\/2) inhibition"],"prefix":"10.1182","volume":"120","author":[{"given":"Michele","family":"Cea","sequence":"first","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"},{"name":"Departments of Internal Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Cagnetta","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"},{"name":"Hematology and Oncology, Istituto Di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliera Universitaria San Martino-IST, Genova, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Fulciniti","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Tzu","family":"Tai","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teru","family":"Hideshima","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharminder","family":"Chauhan","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Roccaro","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Sacco","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Calimeri","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cottini","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Jakubikova","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun-Young","family":"Kong","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"},{"name":"Research Institute and Hospital, National Cancer Center, Goyang, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Patrone","sequence":"additional","affiliation":[{"name":"Departments of Internal Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Nencioni","sequence":"additional","affiliation":[{"name":"Departments of Internal Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Gobbi","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Istituto Di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliera Universitaria San Martino-IST, Genova, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Richardson","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Munshi","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111808555823000_B1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V91.1.3","article-title":"Multiple myeloma: increasing evidence for a multistep transformation process.","volume":"91","author":"Hallek","year":"1998","journal-title":"Blood"},{"issue":"11","key":"2019111808555823000_B2","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nrm2245","article-title":"Autophagy: from phenomenology to molecular understanding in less than a decade.","volume":"8","author":"Klionsky","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"2019111808555823000_B3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1534-5807(04)00099-1","article-title":"Development by self-digestion: molecular mechanisms and biological functions of autophagy.","volume":"6","author":"Levine","year":"2004","journal-title":"Dev Cell"},{"issue":"7137","key":"2019111808555823000_B4","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/446745a","article-title":"Cell biology: autophagy and cancer.","volume":"446","author":"Levine","year":"2007","journal-title":"Nature"},{"issue":"2","key":"2019111808555823000_B5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ceb.2009.10.007","article-title":"mTOR and cancer: many loops in one pathway.","volume":"22","author":"Efeyan","year":"2010","journal-title":"Curr Opin Cell Biol"},{"issue":"6009","key":"2019111808555823000_B6","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1126\/science.1193497","article-title":"Autophagy and metabolism.","volume":"330","author":"Rabinowitz","year":"2010","journal-title":"Science"},{"issue":"6036","key":"2019111808555823000_B7","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1126\/science.1204592","article-title":"TFEB links autophagy to lysosomal biogenesis.","volume":"332","author":"Settembre","year":"2011","journal-title":"Science"},{"issue":"6","key":"2019111808555823000_B8","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.cmet.2007.11.004","article-title":"FoxO3 coordinately activates protein degradation by the autophagic\/lysosomal and proteasomal pathways in atrophying muscle cells.","volume":"6","author":"Zhao","year":"2007","journal-title":"Cell Metab"},{"issue":"24","key":"2019111808555823000_B9","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1073\/pnas.0503221102","article-title":"Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.","volume":"102","author":"Hideshima","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"2019111808555823000_B10","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1158\/1078-0432.CCR-10-0890","article-title":"Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy.","volume":"17","author":"Pan","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2019111808555823000_B11","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2174\/092986708783885282","article-title":"Nicotinamide adenine dinucleotide based therapeutics.","volume":"15","author":"Chen","year":"2008","journal-title":"Curr Med Chem"},{"issue":"1","key":"2019111808555823000_B12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00018-003-3161-1","article-title":"Enzymology of NAD+ homeostasis in man.","volume":"61","author":"Magni","year":"2004","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"2019111808555823000_B13","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.tem.2008.10.004","article-title":"Nampt: linking NAD biology, metabolism and cancer.","volume":"20","author":"Garten","year":"2009","journal-title":"Trends Endocrinol Metab"},{"issue":"49","key":"2019111808555823000_B14","doi-asserted-by":"crossref","first-page":"50754","DOI":"10.1074\/jbc.M408388200","article-title":"The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells.","volume":"279","author":"Revollo","year":"2004","journal-title":"J Biol Chem"},{"issue":"7","key":"2019111808555823000_B15","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.4049\/jimmunol.181.7.4685","article-title":"Nicotinamide phosphoribosyl transferase\/pre-B cell colony-enhancing factor\/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress.","volume":"181","author":"Rongvaux","year":"2008","journal-title":"J Immunol"},{"issue":"2","key":"2019111808555823000_B16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nm.1913","article-title":"NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway.","volume":"15","author":"Skokowa","year":"2009","journal-title":"Nat Med"},{"issue":"5927","key":"2019111808555823000_B17","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1126\/science.1170803","article-title":"Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1.","volume":"324","author":"Nakahata","year":"2009","journal-title":"Science"},{"issue":"5","key":"2019111808555823000_B18","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.devcel.2008.02.004","article-title":"Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt.","volume":"14","author":"Fulco","year":"2008","journal-title":"Dev Cell"},{"issue":"2","key":"2019111808555823000_B19","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nm.1906","article-title":"Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner.","volume":"15","author":"Van Gool","year":"2009","journal-title":"Nat Med"},{"issue":"1","key":"2019111808555823000_B20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.tibs.2006.11.006","article-title":"NAD+ metabolism in health and disease.","volume":"32","author":"Belenky","year":"2007","journal-title":"Trends Biochem Sci"},{"issue":"21","key":"2019111808555823000_B21","first-page":"7436","article-title":"FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.","volume":"63","author":"Hasmann","year":"2003","journal-title":"Cancer Res"},{"issue":"4","key":"2019111808555823000_B22","first-page":"1057","article-title":"WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells.","volume":"62","author":"Wosikowski","year":"2002","journal-title":"Cancer Res"},{"issue":"8","key":"2019111808555823000_B23","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/onc.2010.468","article-title":"NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response.","volume":"30","author":"Wang","year":"2011","journal-title":"Oncogene"},{"issue":"14","key":"2019111808555823000_B24","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2008-08-173369","article-title":"The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies.","volume":"113","author":"Nahimana","year":"2009","journal-title":"Blood"},{"issue":"11","key":"2019111808555823000_B25","doi-asserted-by":"crossref","first-page":"e7897","DOI":"10.1371\/journal.pone.0007897","article-title":"Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE.","volume":"4","author":"Bruzzone","year":"2009","journal-title":"PloS One"},{"issue":"7","key":"2019111808555823000_B26","doi-asserted-by":"crossref","first-page":"e22739","DOI":"10.1371\/journal.pone.0022739","article-title":"Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells.","volume":"6","author":"Cea","year":"2011","journal-title":"PloS One"},{"issue":"8","key":"2019111808555823000_B27","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nature Reviews. Cancer"},{"issue":"4","key":"2019111808555823000_B28","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nm.2112","article-title":"Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.","volume":"16","author":"McMillin","year":"2010","journal-title":"Nat Med"},{"issue":"3","key":"2019111808555823000_B29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4161\/auto.5635","article-title":"NAD depletion by FK866 induces autophagy.","volume":"4","author":"Billington","year":"2008","journal-title":"Autophagy"},{"issue":"3","key":"2019111808555823000_B30","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2010.01.028","article-title":"Methods in mammalian autophagy research.","volume":"140","author":"Mizushima","year":"2010","journal-title":"Cell"},{"issue":"2","key":"2019111808555823000_B31","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4161\/auto.5338","article-title":"Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes.","volume":"4","author":"Klionsky","year":"2008","journal-title":"Autophagy"},{"issue":"5","key":"2019111808555823000_B32","doi-asserted-by":"crossref","first-page":"634","DOI":"10.4161\/auto.6.5.12112","article-title":"A novel quantitative flow cytometry-based assay for autophagy.","volume":"6","author":"Eng","year":"2010","journal-title":"Autophagy"},{"issue":"4","key":"2019111808555823000_B33","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1158\/1078-0432.CCR-10-2634","article-title":"Principles and current strategies for targeting autophagy for cancer treatment.","volume":"17","author":"Amaravadi","year":"2011","journal-title":"Clin Cancer Re"},{"issue":"7","key":"2019111808555823000_B34","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.febslet.2010.01.017","article-title":"mTOR regulation of autophagy.","volume":"584","author":"Jung","year":"2010","journal-title":"FEBS letters"},{"issue":"10","key":"2019111808555823000_B35","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1158\/1535-7163.MCT-05-0068","article-title":"Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor\/insulin receptor substrate-1\/phosphatidylinositol 3-kinase cascade.","volume":"4","author":"Shi","year":"2005","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"2019111808555823000_B36","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/1535-7163.MCT-09-0763","article-title":"Dual inhibition of akt\/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.","volume":"9","author":"Cirstea","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"2019111808555823000_B37","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1182\/blood-2004-04-1670","article-title":"Combined disruption of both the MEK\/ERK and the IL-6R\/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells.","volume":"104","author":"Chatterjee","year":"2004","journal-title":"Blood"},{"issue":"12","key":"2019111808555823000_B38","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/nrc952","article-title":"Molecular mechanisms of novel therapeutic approaches for multiple myeloma.","volume":"2","author":"Hideshima","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"3191","key":"2019111808555823000_B39","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells.","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"issue":"5","key":"2019111808555823000_B40","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1517\/14728222.11.5.695","article-title":"Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery.","volume":"11","author":"Khan","year":"2007","journal-title":"Expert Opin Ther Targets"},{"issue":"6","key":"2019111808555823000_B41","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1046\/j.1432-1327.2000.01187.x","article-title":"New functions of a long-known molecule. Emerging roles of NAD in cellular signaling.","volume":"267","author":"Ziegler","year":"2000","journal-title":"Eur J Biochem"},{"issue":"20","key":"2019111808555823000_B42","doi-asserted-by":"crossref","first-page":"5929","DOI":"10.1021\/bi00368a014","article-title":"Depletion of nicotinamide adenine dinucleotide in normal and xeroderma pigmentosum fibroblast cells by the antitumor drug CC-1065.","volume":"25","author":"Jacobson","year":"1986","journal-title":"Biochem"},{"issue":"1","key":"2019111808555823000_B43","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1083\/jcb.200801099","article-title":"Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents.","volume":"183","author":"Degtyarev","year":"2008","journal-title":"J Cell Biol"},{"key":"2019111808555823000_B44","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-3-540-31209-3_7","article-title":"The mammalian target of rapamycin kinase and tumor growth inhibition.","volume":"172","author":"Boulay","year":"2007","journal-title":"Recent Results Cancer Res"},{"issue":"10","key":"2019111808555823000_B45","doi-asserted-by":"crossref","first-page":"e25820","DOI":"10.1371\/journal.pone.0025820","article-title":"Compromising the unfolded protein response induces autophagy-mediated cell death in multiple myeloma cells.","volume":"6","author":"Michallet","year":"2011","journal-title":"PloS One"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/17\/3519\/1357916\/zh804312003519.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/17\/3519\/1357916\/zh804312003519.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T15:01:13Z","timestamp":1574089273000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/17\/3519\/30613\/Targeting-NAD-salvage-pathway-induces-autophagy-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,25]]},"references-count":45,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2012,10,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-03-416776","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,25]]}}}